Rubinstein-Taybi syndrome (RSTS) is a developmental disorder characterized by a wide spectrum of multiple congenital anomalies and cognitive impairment. RSTS is primarily due to mutations in CREBBP (approximately 55% of cases) or EP300 (approximately 8% of cases) genes. A 2 month-old boy had atypical facial findings such as low anterior hairline, triangular face, hirsutism on forehead, down-slanting palpebral fissures, beaked nose, broad nasal bridge, triangular mouth and pointed chin and skeletal finding including broad great thumbs and halluces, and accessory nipple. With this paper, we reported a novel frameshift mutation which is led to premature stop codon in CREBBP gene. As a result, c.2057dupC, reported in this paper enlarges the molecular spectrum of disease-causing CREBBP gene.
Rubinstein-Taybi Syndrome (RSTS; #180849; #613684) is a rare (1:100,000-125,000) autosomal-dominant congenital disorder characterized by facial dysmorphic features such as prominent beaked nose, columella below the alae nasi and down-slanting palpebral fissures. The cardinal findings of RSTS are skeletal abnormalities (broad thumbs and halluces), postnatal growth retardation and intellectual disability (ranging from mild to severe).¹ , ² Besides congenital heart defects, genitourinary and central nervous system (CNS) malformations, skin anomalies and increased predisposition to cancer (especially tumors of neural crest origin), are among the other manifestations of RSTS.¹ , ³ Inheritance pattern of RSTS is autosomal dominant with variable expression, but reports of transmission are rare, almost all cases are de novo 4 . The genetic etiology of RSTS is heterogeneous and partially known. In approximately 55% of RSTS cases, mutations in cAMP response element-binding protein (CREBBP), located on chromosome 16p13.3, are reported¹. The second gene described in RSTS is E1A-associated protein p300 (EP300, encoding p300), located on chromosome 22q13.2. Mutations in EP300 have been identified in up to 8% of the cases with RSTS. 5, 6 In about 40% of clinically diagnosed cases with RTS, the genetic cause remains unknown.
Herein we report a RTS patient with a novel mutation of the CREBBP gene (c.2057dupC) who presented with atypical facial appearance, feeding difficulties and recurrent respiratory infection.
Case Report
A 2 month-old boy was referred to our department due to his atypical facial appearance and feeding difficulties. His mother was 39-years old and had hypothyroidism. There was no relevant family history. He was born at 39 weeks from a twin pregnancy with a birth weight of 3000 g (25-50th percentile). The second fetus deceased at 20 weeks gestational age. Because of respiratory distress and feeding difficulties, he stayed at the intensive care unit for approximately one month. He experienced recurrent respiratory infection and seizures. At 2 months of age, his height was 54 cm (3-10p), weight 3,500 g (3p) and head circumference 33 cm (<3p). Besides microcephaly, he had large anterior fontanelle, low anterior hairline, triangular face, hirsutism on forehead, downslanting palpebral fissures, beaked nose, broad nasal bridge, triangular mouth, pointed chin, broad great thumbs and halluces, deep plantar creases between 1st and 2nd toes, capillary hemangioma on back of neck and accessory nipple below right nipple (Fig. 1A-C) . Other observed findings included gastroesophageal reflux on esophagography and minimal secundum ASD.
Some clinical findings of the patient such as microcephaly, beaked nose, broad great thumbs/halluces and short stature overlap with RSTS. Sequencing of CREBBP was performed by next-generation sequencing technique. The sequencing reactions were performed using the MiSeq Illumina sequencer (Illumina, San Diego, CA). Data analysis was performed by MiSeq Reporter. Sequencing of CREBBP revealed a C duplication at c.2057 position in the CREBBP gene (c.2057dupC), a frameshift mutation predicted to result in premature termination at the 726th amino acid of CREB binding protein (p.Ala687SerfsTer*39). A written informed consent for the publication of the patient's pictures was given by his parents.
Discussion
RSTS was described in 1963 by Rubinstein and Taybi 4 and found to be caused first by mutations in CREBBP 7 . CREB-binding protein (CBP) is a large protein which includes a bromodomain conserved structural unit critical for protein-protein interactions. The protein serves as a transcriptional coactivator associated with cell development and growth. Chrivia et al. 8 reported the discovery of a nuclear transcriptional coactivator protein, CBP, that binds specifically to the PKA-phosphorylated form of the CREB protein. But CBP also interacts with a large number of other proteins. By means of CBP, it forms a bridge between the DNA-binding transcription factors and the RNA polymerase II complex. In addition, with intrinsic histone acetyl transferase (HAT) activity, CBP opens the chromatin structure of related locus. P300 protein which is encoded by second minor gene, EP300, identified Through histone acetylation, they modify chromatin structure and regulate the expression of a large number of genes. Despite high homology between CBP and P300, both proteins have distinct cellular functions and cannot always replace one another. 9, 10 As far as our knowledge, the mutation presented here, c.2057dupC (p.Ala687SerfsTer*39), has not been reported in the literature to date. Although it was not possible to determine if the mutation was de novo owing to unavailable parental DNA, this mutation is likely to be pathogenic because it leads to premature stop codon. The mutant protein predicted to be free from bromodomain which is important for protein-protein interactions and HAT domain which is a critical fragment for expression of a variety of genes. In addition, these mutant transcripts are targeted for rapid degradation by nonsense-mediated decay (NMD). Molecular modeling of both CREB-binding protein and mutant, p.Ala687SerfsTer*39 CREB-binding protein are shown in Figure 1D and Figure  1E , respectively.
As for CREBBP gene mutation variety, from chromosomal rearrangements to point mutations located nearly the entire length of the gene are reported. To date, >300 mutations are reported in CREBBP according to HGMD (November 2016).¹¹ The mutation spectrum is represented mostly from nonsense and missense (103), and splice site (24) heterozygous mutations. Small deletions or small insertions (96) and gross deletions or gross insertions (89) also have been reported.
There are some phenotypic differences between patients with CREBBP and EP300 mutations, particularly the skeletal findings and intellectual development. 12 In patients with EP300 mutation, skeletal findings and intellectual development also appears to be less affected. In our case, short stature, broad great thumbs and halluces were prominently present; more compatible with CREBBP mutation. In addition, when he was 2 year-old, psychometric evaluation was reported as abnormal but findings were not detailed.
As a result, we present a case with RSTS, which is rare, along with clinical findings and a novel frameshift mutation predicted to result in premature termination, c.2057dupC, in CREBBP gene. In addition, it is important that the mutation reported here enlarges the molecular spectrum of disease-causing CREBBP gene. To enlarge this spectrum and detail genotype-phenotype correlation, clinically diagnosed cases with RSTS should be screened for CREBBP and EP300 gene mutations.
